Taysha Gene Therapies (TSHA)
(Real Time Quote from BATS)
$2.04 USD
+0.02 (0.99%)
Updated Oct 2, 2024 03:04 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Taysha Gene Therapies, Inc. (TSHA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.41 | $8.00 | $5.00 | 217.33% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Taysha Gene Therapies, Inc. comes to $6.41. The forecasts range from a low of $5.00 to a high of $8.00. The average price target represents an increase of 217.33% from the last closing price of $2.02.
Analyst Price Targets (11)
Broker Rating
Taysha Gene Therapies, Inc. currently has an average brokerage recommendation (ABR) of 1.08 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.08 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 91.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 91.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.08 | 1.08 | 1.08 | 1.08 | 1.08 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
8/13/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
8/12/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
8/12/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
8/12/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
6/27/2024 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
6/20/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
6/20/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
6/17/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
6/3/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/1/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.08 |
ABR (Last week) | 1.08 |
# of Recs in ABR | 12 |
Average Target Price | $6.41 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 39 of 252 |
Current Quarter EPS Est: | -0.08 |
TSHA FAQs
Taysha Gene Therapies, Inc. (TSHA) currently has an average brokerage recommendation (ABR) of 1.08 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms.
The average price target for Taysha Gene Therapies, Inc. (TSHA) is $6.41. The current on short-term price targets is based on 5 reports.
The forecasts for Taysha Gene Therapies, Inc. (TSHA) range from a low of $5 to a high of $8. The average price target represents a increase of $217.33 from the last closing price of $2.02.
The current UPSIDE for Taysha Gene Therapies, Inc. (TSHA) is 217.33%
Based on short-term price targets offered by 11 analysts, the average price target for Taysha Gene Therapies, Inc. comes to $6.41. The forecasts range from a low of $5.00 to a high of $8.00. The average price target represents an increase of 217.33% from the last closing price of $2.02.